Compare HMN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | ABCL |
|---|---|---|
| Founded | 1945 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | HMN | ABCL |
|---|---|---|
| Price | $54.94 | $7.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $47.33 | $8.40 |
| AVG Volume (30 Days) | 291.8K | ★ 6.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 57.26 | 10.91 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $1,701,400,000.00 | $75,128,000.00 |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $3.41 | $21.85 |
| P/E Ratio | $54.12 | ★ N/A |
| Revenue Growth | 6.66 | ★ 160.56 |
| 52 Week Low | $40.04 | $2.75 |
| 52 Week High | $54.64 | $8.42 |
| Indicator | HMN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 82.02 | 68.74 |
| Support Level | $41.94 | $3.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.27 | 0.65 |
| MACD | 0.42 | 0.17 |
| Stochastic Oscillator | 91.80 | 84.55 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.